Edgar Filing: DelMar Pharmaceuticals, Inc. - Form 4

DelMar Pharmaceuticals, Inc. Form 4 September 19, 2014

September 19	9, 2014										
FORM	14							-	OMB APPROVAL		
	Washington, D.C. 20549						OMB Number:	3235-0287			
Check thi if no long subject to Section 1 Form 4 or Form 5 obligation may cont <i>See</i> Instru 1(b).	6. Filed Section	pursuant to 17(a) of the	Section 1	SECUR 6(a) of th ility Hole	RITIES e Securit ding Con	ies Ez īpany	xchang Act o	NERSHIP OF te Act of 1934, f 1935 or Sectio 40	Expires: Estimated a burden hou response	rs per	
(Print or Type F	Responses)										
1. Name and A BACHA JE	ddress of Report FFREY	ing Person <u>*</u>	Symbol		Ticker or euticals,		ıg	5. Relationship o Issuer (Che	f Reporting Per		
(Last) (First) (Middle) 3.			3. Date of (Month/D	3. Date of Earliest Transaction (Month/Day/Year) 09/18/2014				XDirector10% Owner XOfficer (give titleOther (specify below)Dther (specify below) CEO and President			
	(Street)	(Street) 4. If Amendmen Filed(Month/Day/			U	l		 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 			
VANCOUV	ER, A1 V5Z	1K5							More than One Re		
(City)	(State)	(Zip)	Table	e I - Non-I	Derivative	Securi	ties Aco	quired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction (Month/Day/Y	ear) Executi any	emed on Date, if /Day/Year)	Code (Instr. 8)	on(A) or D (D)	4 and (A) or	d of 5) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	09/18/2014			Р	4,000	А	\$ 0.98	50,985	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and unt of rlying tities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: DelMar Pharmaceuticals, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
BACHA JEFFREY SUITE 720-999 WEST BROADWAY VANCOUVER, A1 V5Z 1K5	Х		CEO and President				
Signatures							

Jeffrey Bacha	09/19/2014
<u>**</u> Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.